David Dreman

Last Update: 11-14-2017

Number of Stocks: 429
Number of New Stocks: 7

Total Value: $182 Mil
Q/Q Turnover: 4%

Countries: USA
Details: Top Buys | Top Sales | Top Holdings  Embed:

David Dreman' s Profile & Performance

Profile

David Dreman is the founder and Chairman of Dreman Value Management, LLC and also serves as the firm's Chief Investment Officer. A regular columnist for Forbes for 25 years, Mr. Dreman's recent best-selling book, "Contrarian Investment Strategies: The Next Generation?" was published in the spring of 1998.

Web Page:http://www.dreman.com/news/

Investing Philosophy

The Contrarian and the value guru, Dreman's investment philosophy is based on low P/E approach to stock selection. The philosophy at Dreman Value Management: "We invest in undervalued companies that exhibit strong fundamentals, above-market dividend yields and historic earnings growth, which our analysis indicates will persist. Our strategy is to own strong, fundamentally sound companies and to avoid speculative stocks or potential bankruptcies." They believe that the markets are not perfectly efficient, and that behavioral psychology influences investor actions and reactions.

Total Holding History

Performance of Large Cap Value Composite

YearReturn (%)S&P500 (%)Excess Gain (%)
20147.5713.69-6.1
201333.1432.390.8
201212.3316-3.7
3-Year Cumulative60.9 (17.2%/year)74.6 (20.4%/year)-13.7 (-3.2%/year)
2011-8.032.11-10.1
201014.7215.06-0.3
5-Year Cumulative69.7 (11.2%/year)105.1 (15.5%/year)-35.4 (-4.3%/year)
200926.9126.460.5
2008-44.97-37-8.0
2007-1.375.49-6.9
200617.515.791.7
20057.714.912.8
10-Year Cumulative48 (4%/year)109.4 (7.7%/year)-61.4 (-3.7%/year)
200412.6510.881.8

Top Ranked Articles

The Power of Psychology and Low P/Es David Dreman likes to see the market overreact, especially negatively; that means it’s time to go shopping
Own Meritorious Businesses, not Stock Markets What the space race did for tech in the 1960s the internet might be doing for it today
The current circumstance in the U.S. stock market remind us of the mid-1960s. We thought it would be helpful to review what was going on back then and what took place in the following 16 years. It makes us believe that you want to own wonderful businesses and de-emphasize trust in the stock market’s ability to meet the financial goals of long-duration investors. Read more...
Goldcorp Sells Cerro Blanco to Bluestone Resources Miner sells interest for $18 million
Goldcorp Inc. (NYSE:GG) announced Wednesday it agreed to sell its 100% interest in the Cerro Blanco gold-silver project in Guatemala to Bluestone Resources Inc. (TSXV:BSR). Read more...
Express Scripts to Include Harvoni in Hepatitis Cure Value Program The treatment cost will be reduced close to 50%
As announced by Express Scripts (NASDAQ:ESRX) through PR Newswire Dec. 12, the program that targets the treatment of patients affected with the hepatitis C virus, called “Hepatitis Cure Value Program,” will be upgraded with another product in January. Read more...
David Dreman Buys JPMorgan, Kroger, Reynolds Guru's largest 1st-quarter purchases
David Dreman (Trades, Portfolio) is the founder and chairman of Dreman Value Management LLC and also serves as the firm's chief investment officer. During the first quarter the guru bought shares in the following stocks. Read more...
» More David Dreman Articles

Commentaries and Stories

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Gurus Are Investing in These Industrial Companies 5 popular stocks that have positions in several gurus' portfolios Leon Cooperman,David Dreman,Joel Greenblatt,Warren - Gurus Are Investing In These Industrial Companies
According to the GuruFocus All-In-One Screener, the following companies with core business in the industrials sector have positions in gurus' portfolios. More...

  • Currently 4.00/5

Rating: 4.0/5 (2 votes)

The Power of Psychology and Low P/Es David Dreman likes to see the market overreact, especially negatively; that means it’s time to go shopping David Dreman,Warren Buffett - The Power Of Psychology And Low P/Es
More...

GURUS, DAVID DREMAN, DREMAN VALUE MANAGEMENT, PSYCHOLOGY, BEHAVIORAL FINANCE, FORBES, CONTRARIAN, LOW P/E, INVESTING PHILOSOPHY, EFFICIEN MARKETS, BEHAVIORAL PSYCHOLOGY, VALUE INVESTING, MUTUAL FUNDS


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Discarded Value in a Market of Increasing Risk and Uncertainty Wesco Aircraft was oversold in the beginning to leverage its large asset-light diversified revenue stream David Dreman,Barrow Hanley Mewhinney & Strauss,Chu - Discarded Value In A Market Of Increasing Risk And Uncertainty
Wesco Aircraft (WAIR) sparked my interest after ranking value attributes for a basket of over 3,000 companies. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

David Dreman’s Top 5 Health Care Buys for the 2nd Quarter Guru takes new positions in stocks he previously sold David Dreman,Vanguard Health Care Fund,Jana Partne - David Dreman’s Top 5 Health Care Buys For The 2nd Quarter
Dreman Value Management founder David Dreman (Trades, Portfolio) established 210 new positions in the second quarter, of which 20 were in health care companies. His top five health care buys were Aetna Inc. (NYSE:AET), Zimmer Biomet Holdings Inc. (NYSE:ZBH), Amgen Inc. (NASDAQ:AMGN), Biogen Inc. (NASDAQ:BIIB) and Cardinal Health Inc. (NYSE:CAH). More...

DREMAN, BUYS, HEALTHCARE, 2Q


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

David Dreman Exits Total, Reduces Bank of America, Apple The guru's largest 2nd-quarter sells David Dreman - David Dreman Exits Total, Reduces Bank Of America, Apple
Dreman Value Management founder David Dreman (Trades, Portfolio) exited or reduced his positions in the following stocks during the third quarter: More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

7 Stocks Trading Below the Peter Lynch Value Companies have wide margins of safety Chuck Royce,David Dreman,Jeremy Grantham,Mario Gab - 7 Stocks Trading Below The Peter Lynch Value
According to the GuruFocus All-in-One Screener, several gurus are focusing on stocks whose Peter Lynch fair values are far above the current prices. The following stocks are trading with wide margins of safety and have positive performances over the past 12 months. More...

  • Currently 5.00/5

Rating: 5.0/5 (1 vote)

Foot Locker Is the Hidden Gem of Retail Company continues to drive revenue up while increasing gross margins George Soros,David Dreman,Leon Cooperman,Joel Gree - Foot Locker Is The Hidden Gem Of Retail
While the retail industry as a whole is going through major adjustments, one bright spot is Foot Locker (NYSE:FL). More...

RETAIL, COSTCO, WALMART, FOOT LOCKER, SHOES, SNEAKERS, SNEAKER HEADS


  • Currently 3.00/5

Rating: 3.0/5 (1 vote)

6 Stocks With Rising EPS DCF calculator gives wide margins of safety Chuck Royce,David Dreman,Paul Tudor Jones,Steven C - 6 Stocks With Rising EPS
Companies with growing earnings per share (EPS) are often good investments as they can return a solid profit to investors. Here is a selection of the most undervalued companies that have five-year growing EPS, according to the DCF calculator. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

David Dreman Buys JPMorgan, Kroger, Reynolds Guru's largest 1st-quarter purchases David Dreman,Jim Simons,Pioneer Investments,Barrow - David Dreman Buys JPMorgan, Kroger, Reynolds
David Dreman (Trades, Portfolio) is the founder and chairman of Dreman Value Management LLC and also serves as the firm's chief investment officer. During the first quarter the guru bought shares in the following stocks. More...

  • Currently 5.00/5

Rating: 5.0/5 (1 vote)

Own Meritorious Businesses, not Stock Markets What the space race did for tech in the 1960s the internet might be doing for it today David Dreman - Own Meritorious Businesses, Not Stock Markets
The current circumstance in the U.S. stock market remind us of the mid-1960s. We thought it would be helpful to review what was going on back then and what took place in the following 16 years. It makes us believe that you want to own wonderful businesses and de-emphasize trust in the stock market’s ability to meet the financial goals of long-duration investors. More...

VALUE, MARKETS, CONTRARIAN, TECH


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Insiders Invest in National General Holdings CEO, executive vice president purchase 74,978 shares total David Dreman, Scott Black - Insiders Invest In National General Holdings
CEO Barry Karfunkel and Executive Vice President Robert Karfunkel purchased a combined 74,978 shares of National General Holdings Corp. (NASDAQ:NGHC) on March 27 and March 28, according to SEC filings. More...

  • Currently 4.00/5

Rating: 4.0/5 (1 vote)

Is Williams-Sonoma a Better Bargain Than Ever? The retailer's investment prospects after its recent price decline Joel Greenblatt,David Dreman,Ray Dalio,Ken Fisher - Is Williams-Sonoma A Better Bargain Than Ever?
(Published by Nicholas McCullum on March 19) More...

DIVIDENDS, RETAIL


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

AbbVie Regimen Recommended for HCV Infection VIEKIRAX + EXVIERA shows high cure rates in GT1b HCV patients David Dreman,Joel Greenblatt,Ken Fisher,Mario Gabe - AbbVie Regimen Recommended For HCV Infection
AbbVie Inc. (NYSE:ABBV) communicated through the PRNewswire Monday that it received a positive feedback from the European Committee for Medicinal Products for Human Use (CHMP) about the possibility of using VIEKIRAX plus EXVIERA in a combined therapy of eight weeks to treat chronically genotype 1b HCV-infected adult patients. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

AbbVie Declares Quarterly Dividend Analysts forecast increases in 2017 EPS and sales David Dreman, Joel Greenblatt, Mario Gabelli, Ken  - AbbVie Declares Quarterly Dividend
AbbVie Inc. (NYSE:ABBV) annouced a quarterly dividend of 64 cents per share on Feb. 16. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

AbbVie's Hepatitic C Treatment Under Accelerated Review by EMA Treatment is still waiting for FDA approval David Dreman,Joel Greenblatt - AbbVie's Hepatitic C Treatment Under Accelerated Review By EMA
 AbbVie Inc. (NYSE:ABBV) announced Tuesday through the PR Newswire that the European Medicines Agency has validated its marketing authorization application. The company's application seeks permission to rapidly bring its “investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P)” to the market. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Goldcorp Sells Cerro Blanco to Bluestone Resources Miner sells interest for $18 million David Dreman,First Eagle Investment - Goldcorp Sells Cerro Blanco To Bluestone Resources
Goldcorp Inc. (NYSE:GG) announced Wednesday it agreed to sell its 100% interest in the Cerro Blanco gold-silver project in Guatemala to Bluestone Resources Inc. (TSXV:BSR). More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

HollyFrontier Upgraded by Deutsche Bank The firm set a target price of $38 David Dreman,Keeley Asset Management Corp - HollyFrontier Upgraded By Deutsche Bank
HollyFrontier Corp. (NYSE:HFC) has been upgraded by Deutsche Bank, which now suggests buying shares of the refining company. Prior to this rating, Deutsche Bank released a hold on shares of HollyFrontier. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Desjardins Capital Markets Picks Goldcorp for 2017 Company's outlook on output and costs will be appealing for many years First Eagle Investment,David Dreman,Mario Gabelli - Desjardins Capital Markets Picks Goldcorp For 2017
Goldcorp Inc. (NYSE:GG) appears at the top of the list of Desjardins Capital Markets for the large-cap stocks that the firm recommends buying for 2017. The firm says the company “will be able to illustrate an attractive multiyear guidance outlook on both production and costs,” as reported by the Financial Post. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

5 Best Contrarian Stocks for Your Portfolio Here's a breakdown of the 5 top stocks based on the Contrarian Approach David Dreman - 5 Best Contrarian Stocks For Your Portfolio
(This article appeared first on The Stock Market Blueprint Blog.) More...

VALUE STOCKS, QUICK PICKS, LONG, CONTRARIAN STOCKS, DAVID DREMAN


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Gilead Sciences Must Answer to Investors After a Disappointing 2016 Investors are concerned about the company's lack of a plan for the future David Dreman,John Rogers - Gilead Sciences Must Answer To Investors After A Disappointing 2016
Gilead Sciences Inc. (NASDAQ:GILD) delivered a poor performance last year. The stock lost over 24% in 2016, caused by a drop in sales of products that treat hepatitis C. According to Ben Levinsohn in a Barron's article, the decline was also attributed to the company’s lack of a plan for the future. More...

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK